First-in-Class CD146-Targeting Peptide Probes for Noninvasive PET Imaging of Melanoma
Molecular Pharmaceutics · 03.08.2026 · 23 (8) · 4155-4165
DOI: 10.1021/acs.molpharmaceut.6c00184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 07.07.2026. Verfasst von Qian Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: GuiZhou University Medical College , Guiyang550025, Guizhou Province, China. Hauptthemen laut MEDLINE: CD146 Antigen, Melanoma, Positron-Emission Tomography, Peptides. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Yunnan Provincial Science and Technology Department, Youth Beijing Scholar 2024, Science Foundation of Peking University Cancer Hospital.
Abstract (Originalsprache)
The transmembrane glycoprotein CD146, overexpressed in solid tumors and tumor vasculature, is a compelling target reinforced by CD146-targeting antibody-drug conjugates (ADCs) in clinical trials. This development underscores the unmet need for noninvasive imaging tools to guide patient selection. Here, we report the first [68Ga]Ga-labeled peptide-based molecular imaging agents targeting CD146: [68Ga]Ga-DOTA-P1 and [68Ga]Ga-DOTA-P2. Both probes were reliably synthesized with radiochemical yield >90% within 15 min and radiochemical purity exceeding 95% (n = 5). [68Ga]Ga-DOTA-P1 and [68Ga]Ga-DOTA-P2 have good in vitro stability, and high affinity for CD146-positive cell, with Kd values of 152.3 nM and 205.1 nM, respectively. In vitro cellular assays demonstrated specific binding, and fluorescence imaging with the analog FITC-P1 visually confirmed robust CD146-mediated cellular uptake. In vivo PET/CT imaging demonstrated rapid tumor uptake and tissue excretion. A375 model showed a higher tumor-to-muscle ratio (5.33 ± 0.58) with [68Ga]Ga-DOTA-P1 at 30 min, whereas [68Ga]Ga-DOTA-P2 produced lower contrast (2.55 ± 0.58) due to its slower blood clearance; in addition, the imaging ability of [68Ga]Ga-DOTA-P1 was also verified in another CD146-positive model (SK-Mel-28). An immunohistochemical test was performed to assess CD146 distribution, showing low expression in normal tissues versus positive membrane-localized expression in A375 and SK-Mel-28 tumors. This work establishes [68Ga]Ga-DOTA-P1 as a rapid, high-contrast imaging tool for CD146-expressing malignancies, offering a practical strategy for noninvasive patient stratification in the era of targeted CD146 therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GuiZhou University Medical College , Guiyang550025, Guizhou Province, China.
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceu…
Förderung
- Yunnan Provincial Science and Technology Department
- Youth Beijing Scholar 2024
- Science Foundation of Peking University Cancer Hospital
- Beijing Research Ward Excellence Program BRWEP
Zitieren
APA
Zhang, Q., Guo, X., Hao, S., Chen, Q., Jiang, Y., Zhang, Y., Cao, H., Zhu, H., Yang, Z., & Liu, T. (2026). First-in-Class CD146-Targeting Peptide Probes for Noninvasive PET Imaging of Melanoma. Molecular Pharmaceutics, 23(8), 4155-4165. https://doi.org/10.1021/acs.molpharmaceut.6c00184
Vancouver
Zhang Q, Guo X, Hao S, Chen Q, Jiang Y, Zhang Y, et al. First-in-Class CD146-Targeting Peptide Probes for Noninvasive PET Imaging of Melanoma. Molecular Pharmaceutics. 2026;23(8):4155-4165. doi:10.1021/acs.molpharmaceut.6c00184
BibTeX
@article{Zhang2026,
author = {Zhang, Qian and Guo, Xiaoyi and Hao, Siqi and Chen, Qian and Jiang, Yang and Zhang, Yan and Cao, Huanhuan and Zhu, Hua and Yang, Zhi and Liu, Teli},
title = {First-in-Class CD146-Targeting Peptide Probes for Noninvasive PET Imaging of Melanoma},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {8},
pages = {4155--4165},
doi = {10.1021/acs.molpharmaceut.6c00184}
}
EUVIMED